CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction
Linjie Luo(The University of Texas MD Anderson Cancer Center), Khandan Keyomarsi(The University of Texas MD Anderson Cancer Center)
Cited by 3
Related Papers
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
|Nature Communications|2017|290
LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients
|PLoS Genetics|2012|38
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer
|npj Precision Oncology|2025|10